Paramount Capital

Paramount Capital is a global privately held pharmaceutical development and healthcare investment firm categorized under Financial Advisory Services. It is located in New York City.
The company is a conglomerate of firms including: Paramount BioSciences, Paramount BioCapital, Paramount Acquisition Company, Paramount Corporate Development, and Paramount BioCapital Asset Management. All of these companies represent separate entities, but interact to aid each other. For more than 19 years, the Paramount Capital group of companies supports the development of novel drugs and therapies, maintaining a solid commitment to cutting-edge therapies and medications with high potential.
Background
Paramount Capital, Inc., was founded by Lindsay A. Rosenwald, M.D., in 1991. More than forty start-up companies, including Bradley Pharmaceuticals, Inc., Cougar Biotechnology, Cypress Bioscience, Inc., Genta, Inc, Innovive Pharmaceuticals, Novadel Pharma, Ziopharm Oncology, Tikvah Therapeutics, Inc., VioQuest Pharmaceuticals, Bionovo Inc., and many others have been created over the past 19 years.
Since its establishment, Paramount Capital and its divisions have been involved in the clinical development of more than 50 drug candidates, among which some have reached the market (including Arsenic Trioxide, leukemia drug that progressed from Investigational New Drug to New Drug Application in 30 months, which is considered to be one of the fastest regulatory approvals in U.S. Food and Drug Administration (FDA) history; milnacipran for fibromyalgia syndrome licensed from Pierre Fabre Medicament; Sulodexide (KRX-101) for diabetic nephropathy licensed into Keryx Biopharmaceuticals, Inc.; CH-1504 (MobileTrex) for rheumatoid arthritis licensed from University of South Alabama College Of Medicine by Chelsea Therapeutics. More than 30 compounds are still undergoing clinical development today.
Paramount business units
Paramount Biosciences is at the core of the Paramount Capital Group. It is the assessment division of the company with around 40 employees in eight offices located globally. The main focus of Paramount BioSciences is the in-licensing of novel therapeutic and other medical technologies.
Paramount BioCapital is a broker company registered by the Financial Industry Regulatory Authority (FINRA) that offers a wide range of services. The focus of Paramount BioCapital is to generate capital while allowing for successful long-term investment.
Paramount Corporate Development is an additional operations group established to help growing companies from a business standpoint. This group works closely with Paramount BioSciences and the Paramount portfolio companies on in-licensing activities and drug development.
Paramount Acquisition Company is a FINRA-registered broker/dealer that creates unique private equity vehicles to match large pools of capital with late-stage private companies.
Paramount BioCapital Asset Management specializes in buying and selling equities of global healthcare companies through a mixture of national and foreign hedge funds along with private equities to manage their investor assets.
Paramount infrastructure
Paramount Capital, Inc. operates its portfolio companies through a dedicated management at the company level. It also provides all the aspects of business development, clinical development and as well as allocates operations specialists working for Paramount in New York City. This allows new companies to remain focused on the development of drug candidates rather than building infrastructure of their own. They believe that this model helps limit developmental delays and facilitate management effectiveness and offers starts up companies proficiently bring novel therapeutics to the market. Paramount’s portfolio companies are supported in all aspects of management and corporate development, including regulatory, financial, clinical development and legal matters.
Notable employees
*Lindsay A. Rosenwald, MD, Chairman and CEO of Paramount Capital group of companies
*John Graham, President of Paramount Corporate Development
*Peter M. Kash, Co-Founder and Senior Managing Director of Paramount Capital Asset Management, Inc.
*Michael J. Rosenman, Senior Managing Director
*Bryan Leigh, MD, Chief Medical Officer
*J. Jay Lobell, MD, Registered Representative
*Michael Weiser, MD, PhD., Director of Research
*David Benshoof Klein, Managing Director & Head of Global Recruiting at Paramount BioCapital
*Timothy McInerney, former Managing Director of Paramount Biocapital, Inc.
Media coverage
Business People; A Time Investor Sees Gains in Warner Deal
Life's Work; Helping Hands, but Not Quite Mentors
U.S. Securities and Exchange Commission Archives
Sale of One Financial Square Closes for $751 M.
Molecular millionaires Interneuron executives top Massachusetts list
Procept Decides to Bank on Verity of Life: Death Firm Shifts From Biotech to Net Funeral Business

Main Menu

See Also

Main Menu